Click on, or paste the following link into your web browser, to view the associated PDF document. $\underline{\text{http://www.rns-pdf.londonstockexchange.com/rns/4195l}} \underline{\text{1-2025-5-13.pdf}}$

Commercial International Bank (Egypt) S.A.E.

Sepa

	0 Notes	Mar. 31, 2025	Dec. 31, 2024
Assets			
Cash and balances at the central bank	9	67,709,656	136,165,920
Due from banks	10	314,144,761	270,089,441
Loans and advances to banks, net	12	16,109,873	9,555,410
Loans and advances to customers, net	13	361,830,507	340,955,698
Derivative financial instruments		930,893	819,711
Financial investments			
- Financial Assets at Fair Value through OCI	14	259,396,282	233,029,903
- Financial Assets at Amortized cost	14	188,018,472	167,276,956
Investments in subsidiaries and associates	15	853,165	871,525
Non-current assets held for sale	28	159,828	159,828
Other assets	16	40,366,933	44,175,232
Deferred tax assets		2,536,325	2,337,304
Property and equipment	17	4,597,989	3,881,620
Total assets		1,256,654,684	1,209,318,548
Liabilities and equity			
Liabilities			
Due to banks	18	4,051,736	2,317,715
Due to customers	19	996,119,565	967,895,387
Derivative financial instruments		78,314	100,571
Current income tax liabilities		5,565,862	18,327,968
Other liabilities	20	45,946,585	21,347,499
Issued debt instruments	21	5,044,951	5,067,781
Other loans		23,948,624	23,962,389
Other provisions	22	19,032,774	18,613,060
Total liabilities		1,099,788,411	1,057,632,370
Equity			
Issued and paid capital		30,431,580	30,431,580
Reserves		87,850,844	63,125,912
Reserve for employee stock ownership plan (ESOP)		2,184,420	1,868,235
Retained earnings*		36,399,429	56,260,451
Total equity and net profit for the period/year		156,866,273	151,686,178
Total liabilities and equity		1,256,654,684	1,209,318,548

###

The accompanying notes are an integral part of these financial statements. (Review report attached)

*Including net profit for the period

Islam Zekry Group CFO & Executive Board Member

Hisham Ezz Al-Arab CEO & Executive Board Member

Condensed Separate Interim Income Statement for the period ended March 31, 2025

		Last 9 Months	Last 9 M
	Notes	Mar. 31, 2025	Mar. 31,
Interest and similar income		52,299,641	36,544,
Interest and similar expense		(27,003,143)	(17,784,
Net interest income		25,296,498	18,760,
Fee and commission income		3,510,324	2,684,2
Fee and commission expense		(1,586,144)	(1,118,9
Net fee and commission income		1,924,180	1,565,3
Dividend income		12,751	610
Net trading income	6	641,395	16,202,
Profits (Losses) on financial investments	14.1	376,684	224,2'
Administrative expenses		(3,748,977)	(2,840,4
Other operating income (expenses)	7	(1,735,421)	(14,923,
Impairment release (charges) for credit losses		(68,528)	(1,482,1
Profit before income tax		22,698,582	17,507,
Income tax expense	26	(6,514,216)	(5,722,4
Deferred tax assets (Liabilities)	26	411,246	161,8′
Net profit for the period		16,595,612	11,946,
Earnings per share	8		
Basic		4.83	3.47
Diluted		4.79	3.45

Islam Zekry Group CFO & Executive Board Member

Hisham Ezz Al-Arab CEO & Executive Board Membel

Condensed Separate Interim Statement of Comprehensive Income for the period ended March 3
Net profit for the period
Net change on financial assets at fair value through comprehensive income after tax
Effect of ECL on fair value of debt instruments measured at fair value through comprehensive incom
Total comprehensive income for the period

Condensed Separate Interim Cash Flows for the period ended March 31, 2025

	Notes	Mar. 31, 2025	Mar. 31, 2024
Cash flow from operating activities			
Profit before income tax		22,698,582	17,507,212
Adjustments to reconcile profits to net cash provided by operating activities			
Fixed assets depreciation	17	353,476	261,427
Impairment release/charge for credit losses (Loans and advances to customers and banks)		(1,099,420)	1,772,387

Other provisions release/charge	22	317,074	40,759
Impairment release/charge for credit losses (due from banks)		144,661	(53)
Impairment release/charge for credit losses (financial investments)		1,023,287	(290,147)
Impairment release/charge for other assets		-	(4,782)
Exchange revaluation differences for financial assets at fair value through OCI and AC		212,785	(17,328,576)
Revaluation differences impairment charge for Financial Assets at Fair value through OCI		(13,337)	1,130,412
Revaluation differences impairment charge for Financial Assets at Amortized cost		1,240	95,225
Revaluation differences impairment charge for due from banks		-	101
Net utilized / recovered of other provisions	22	(520)	(4,517)
Exchange revaluation differences of other provisions	22	103,160	3,574,794
Profits/losses from selling property and equipment		(6,006)	-
Profits/losses from selling financial investments at fair value through OCI	14.1	(195,124)	(224,271)
Profits/losses from selling investments in associates	14.1	(181,560)	-
Share based payments		316,185	300,000
Operating profits before changes in operating assets and liabilities		23,674,483	6,829,971
Net decrease / increase in assets and liabilities			
Due from banks		121,695,741	42,289,034
Financial assets at fair value through P&L		-	(974,297)
Derivative financial instruments		(142,036)	154,638
Loans and advances to banks and customers		(26,329,852)	(36,747,889)
Other assets		6,045,337	(5,850,432)
Due to banks	18	1,734,021	(6,855,319)
Due to customers	19	28,224,178	117,099,122
Current income tax obligations paid		(948,354)	(276,723)
Other liabilities		5,716,835	1,851,912
Net cash generated from (used in) operating activities		159,670,353	117,520,017
Cash flow from investing activities			
Proceeds from sale of investments in associates		226,698	4,782
Payments for investment in subsidiaries		(140,000)	-
Payments for purchases of property, equipment and branches construction		(3,193,660)	(366,618)
Proceeds from selling property and equipment		6,006	-
Proceeds from redemption of financial assets at amortized cost		2,537,401	285,507
Payments for purchases of financial assets at amortized cost		(23,457,385)	(53,240,480)
Payments for purchases of financial assets at fair value through OCI		(29,004,342)	(26,284,875)
Proceeds from selling financial assets at fair value through OCI		6,057,967	26,380,625
Net cash generated from (used in) investing activities		(46,967,315)	(53,221,059)
		Mar. 31, 2025	Mar. 31, 2024
Cash flow from financing activities		(13,765)	6,700,881
· ·			. , ,
Other loans		* * *	(5,078,792)
Other loans Dividends paid		(14,160,152) (22,830)	(5,078,792) 1,626,167
Other loans Dividends paid Issued debt instruments		(14,160,152)	
Other loans Dividends paid Issued debt instruments		(14,160,152) (22,830)	1,626,167
Cash flow from financing activities Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities Net (decrease) increase in cash and cash equivalent during the period		(14,160,152) (22,830) (14,196,747) 98,506,291	1,626,167 3,248,256 67,547,214
Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities Net (decrease) increase in cash and cash equivalent during the period Beginning balance of cash and cash equivalent		(14,160,152) (22,830) (14,196,747) 98,506,291 227,028,744	1,626,167 3,248,256 67,547,214 233,912,193
Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities Net (decrease) increase in cash and cash equivalent during the period Beginning balance of cash and cash equivalent		(14,160,152) (22,830) (14,196,747) 98,506,291	1,626,167 3,248,256 67,547,214
Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities		(14,160,152) (22,830) (14,196,747) 98,506,291 227,028,744	1,626,167 3,248,256 67,547,214 233,912,193
Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities Net (decrease) increase in cash and cash equivalent during the period Beginning balance of cash and cash equivalent Cash and cash equivalent at the end of the period Cash and cash equivalent comprise:	9	(14,160,152) (22,830) (14,196,747) 98,506,291 227,028,744	1,626,167 3,248,256 67,547,214 233,912,193
Other loans Dividends paid Issued debt instruments Net cash generated from (used in) financing activities Net (decrease) increase in cash and cash equivalent during the period Beginning balance of cash and cash equivalent Cash and cash equivalent at the end of the period	9	(14,160,152) (22,830) (14,196,747) 98,506,291 227,028,744 325,535,035	1,626,167 3,248,256 67,547,214 233,912,193 301,459,407

Obligatory reserve balance with CBE	(43,/18,398)	(19,383,018)
Due from banks with maturity more than three months	(14,867,792)	(7,554,480)
Treasury bills and other governmental notes with maturity more than three months	(113,842,898)	(119,880,325)
Total cash and cash equivalent	325,535,035	301,459,407

Condensed Separate Interim statement of changes in shareholders' equity

	Issued and paid capital	Legal reserve Ge
Mar. 31, 2024		
Beginning Balance at 1 January 2024	30,195,010	4,770,354
Transferred to reserves	-	1,438,320
Dividend paid	-	-
Net profit for the period	-	-
Net change on financial assets at fair value through OCI after tax	-	-
Transferred (from) to banking risk reserve	-	-
Effect of ECL in fair value of debt instruments measured at fair value through OCI	-	-
Cost of employees stock ownership plan (ESOP)	-	-
Balance at 31 March 2024	30,195,010	6,208,674

 $\begin{array}{c} \underline{\textbf{Issued and paid}} \\ \underline{\textbf{capital}} \end{array} \ \underline{\textbf{Legal reserve}} \ \ \underline{\textbf{Ge}}$

Beginning Balance at 1 January 2025	30,431,580	6,208,674
Transferred to reserves	-	2,771,284
Dividends paid	-	-
Net profit for the period	-	-
Net change on financial assets at fair value through OCI after tax	-	-
Transferred (from) to banking risk reserve	-	-
Effect of ECL in fair value of debt instruments measured at fair value through OCI	-	-
Cost of employees stock ownership plan (ESOP)	-	
Balance at 31 March 2025	30,431,580	8,979,958



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

QRFEXLBFEELBBBQ